当前位置:首页 > 关于我们 > 创投导师 > 李湘

李湘 | Shawn Lee


李湘.jpg

李湘

中肽生化创始人/董事长;泽悦资本联合创始人。中美两地连续创业成功的科学家、企业家,国家高层次人才专家;“国家重大专项新药”评审专家;中国侨联特聘专家;浙商总会常务理事;信邦制药【002390】前副董事长,

李湘博士在美国硅谷创办多家公司包括American Peptide Co.; CPC Scientific Inc, etc. 李湘博士拥有中科院化学博士学位,加大伯克利分校博士后,长江商学院,瑞士IMD商学院EMBA,美国太平洋大学药学院客座教授。

李博士是全球多肽领域领先企业中肽生化的创始人,带领着由国际水准的专家组成的研发团队,在多肽研发领域保持全球领先水平。做为被FDA现场检查的第一家亚洲多肽公司,中肽连续四次零缺陷通过FDA现场检查 ,欧盟新药现场核查以及韩国KFDA现场核查。

中肽生化有限公司成立于2001年,总部位于浙江杭州,是值得信赖的全球一体化多肽CRO/CDMO合作伙伴,专注多肽行业近20年。中肽在国内和美国硅谷均设有研究基地,并坚持遵循高效、优质、专业、创新的理念和为客户创造“优秀价值”的服务宗旨,多年来致力于赋能多肽类新药和仿制药的原料药,制剂研发、申报及大规模商业化生产


Shawn Lee

Founder / Chairman of Chinese Peptide Company; co-founder of Zeyue Capital. Scientists and entrepreneurs in China and the United States, national high-level talent experts, national major special new drug evaluation experts, special experts of All-China Federation of Overseas Chinese, executive director of Zhejiang chamber of Commerce, and former vice chairman of Xinbang pharmaceutical [002390],

Dr.Shawn Lee founded a number of Companies in Silicon Valley, including American Peptide Co.; CPC Scientific Inc, etc. Dr. Shawn Lee holds a Ph.D. degree in chemistry from the Chinese Academy of Sciences, a postdoctoral degree from Berkeley, CKGSB, EMBA of IMD business school in Switzerland, and a visiting professor of Pharmacy School of Pacific University in the United States.

Dr. Lee is the founder of Peptide Biochemistry, a leading company in the global peptide field. He leads the R&D team composed of international level experts and maintains the global leading level in the peptide R&D field. As the first Asian polypeptide company to be inspected by FDA on-site, Peptide has passed FDA on-site inspection, EU new drug on-site inspection and Korea KFDA on-site inspection for four consecutive times with zero defect.

Established in 2001 and headquartered in Hangzhou, Zhejiang Province, Chinese Peptide Biochemical Co., Ltd. is a reliable global CRO/CDMO partner focusing on peptide industry for nearly 20 years. Peptide has set up research bases in China and Silicon Valley of the United States,  adhering to the concept of high efficiency, high quality, professional and innovation as well as  the service tenet of creating "excellent value" for customers, and has been committed to the research and development, application and large-scale commercial production of API, preparation of enabling peptide new drugs and generic drugs.


0.176553s